Live: ACHEMA Opening Day Report - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Live: ACHEMA Opening Day Report



In 2009 there were 3767 exhibitors and more than 173000 visitors to ACHEMA in Frankfurt. The 2012 event looks to be even bigger. The hot topics for this year are energy and resources, while congress topics will address process engineering, pharmaceutical production and biotechnology. On the opening day, I saw a variety of new technologies for the pharma industry.

Lock showcased a gravity fall metal detection system that promises a greater product integrity for API manufacturers. They also have a bottlecheck system that incorporates an 'OPTIX' detector that inspects bottles of tablets and capsules at the end of the packaging line.

Thomas Homann of GEA showed me a separator for the recovery of vaccines and pharmaceutical proteins in lab scale and pilot plant applications. It operates at 20000G, which is unique worldwide. There are three bowl sizes, 15-30 L/h up to 150-300L/h. Of course, it is a sterile system that meets GMP requirements.

Merck Millipore have the only complete single-use process train that promises scalable, industry standard separation and purification technologies. The highest level of flexibility for multi-product, multi-scale facilities with modular units for scaling up, down and across unit operations.

More news to come soon!

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here